ODI Pharma (ODI) Q2 2025 earnings summary

Executive summary

• Net sales for the group were SEK 0 in Q2 2024/25, down from SEK 1,175 in Q2 last year; six-month net sales were SEK -4,965 versus SEK 780,209 year-over-year.

• Net loss after financial items was SEK -2,562,520 in Q2 (vs. profit of SEK 946,531 last year); six-month loss was SEK -3,953,290 (vs. -491,846).

• Rights issue completed in December 2024 raised SEK 2.2 million before costs, strengthening financial position.

• Leadership changes: Jan-Mark Edewaard appointed CEO effective January 2025; Malcolm Allan proposed as new board member.

• Focus remains on the Polish medical cannabis market, where ODI captured over 10% market share.

Financial highlights

• Q2 group revenue: SEK 74,034 (vs. SEK 2,950,940 last year); operating income: SEK -2,319,054 (vs. SEK 1,059,104).

• Six-month group net loss: SEK -3,953,314 (vs. SEK -491,858); EPS: SEK -0.25 (vs. -0.03).

• Group solidity at 7% (vs. 28% last year); total assets SEK 6,628,026 (vs. SEK 7,345,743).

• Cash flow from operations in Q2: SEK -1,929,767 (vs. SEK 882,383); cash at period end: SEK 5,358,786.

• No long-term liabilities; equity at SEK 445,012 (vs. SEK 2,036,218 last year).

Outlook and guidance

• Continued order flow and expanded import volumes in Poland support growth plans.

• Improved financial base and updated leadership position ODI for future opportunities in the European medical cannabis market.